asthma and copd
TRANSCRIPT
04/08/23 1
Asthma and COPD
Isabelita M. Samaniego MD, MOH, FPAFPMa. Eufemia M. Collao, MD, DPAFP
FCM 3 – College of MedicinePamantasan ng Lungsod ng Maynila
04/08/23 2
04/08/23 3
Session Objectives
To describe the symptomatology in asthma & COPD
To describe the disease severity according to lung function based on GINA and GOLD.
To describe the definition of disease control & treatment objectives for asthma & COPD
To describe the national objectives for health for asthma & COPD.
04/08/23 4
Symptomatomatology
Asthma Intermittent & feeling
well in between Frequent to persistent
& rarely feeling completely well
Intermittent cough frequently dry
COPD Frequent cough usually
wet mostly in the morning.
Can become so well that asthma is seemingly cured
Never full recovery usually getting progressively worse
04/08/23 5
Disease Severity According to lung function GINA & GOLD Asthma COPD
NoneStage 0 =FEV1> 80%
( At risk) =FEV1/FVC>70%
Step 1= PEFR or FEV1 > 80%
( Intermittent)
Stage 1 = FEV1 > 80%
( Mild) = FEV1/FVC < 70%
Step 2 = PEFR or FEV1 > 80%
( Mild persistent)
Stage 2= 50% < FEV1 < 80%
Moderate =FEV1/FVC < 70%
Step 3 = PEFR < 60% orFEV1 < 80%
(Moderate Persistent)
Stage 3 = 30% < FEV1 < 50%
Severe =FEV1/FVC < 70%
Step 4 PEFR or FEV1 < 60%
( Severe persistent)
Stage 4=FEV1 < 30%
( Very severe) = FEV1/FVC < 70%
Chronic Resp. & heart failure
04/08/23 6
Definition of Disease Control & Treatment Objectives for Asthma & COPD Asthma= GINA Minimal episodes No emergency visits Minimal need for prn B2 agonist No limitations on activities,
including exercise PEF variability <20% ( Near normal PEF) Minimal or no adverse effects from
medicine.Summary:
To achieve total absence of symptoms of wheeze, breathlessness & cough, normal or near normal lung function.
COPD= GOLD Prevent disease progression Relieve symptoms Improve exercise tolerance Improve health status Prevent & treat exacerbations Prevent & treat complications Reduce mortality Minimize side effectsSummary :
To prevent the progression of the disease ( lung function deterioration) & to improve the health status or quality of life of patients as
much as possible.
04/08/23 7
04/08/23 8
Goal
To reduce asthma-related mortality and morbidity
04/08/23 9
Health Status Objectives Limit the prevalence of asthma to no more
than 12% Risk Reduction Objectives
Increase the awareness of patient and family on factors that trigger or precipitate asthma to 30%
Increase knowledge of the signs and symptoms of asthma by patients, families and the general public to 50%
04/08/23 10
Services and Protection Objectives
Establish baseline data on the prevalence of asthma in the Philippines in 2000
Expand the coverage of asthma clubs in coordination with the National Asthma Movement to 75%
Operationalize Asthma Education Prevention and Control Programs in 2000
04/08/23 11
Philippine Report on Asthma 2004
04/08/23 12
Epidemiolgy
Asthma is a common disease Highest prevalence in UK, Australia, NZ
Increasing trend for all ages, sex, and racial groups Prevalence increasing by 4%/yr Higher among children than adults (esp males),
blacks than whites, impoverished children
International Study of Asthma and Allergies in Children ( ISAAC) , 1995
04/08/23 13
Philippine Picture
No available nationwide data on asthma prevalence.
Limited reports: prevalence of 12% in children 13-14y/o and 17-22% in older age grps
Lung Center (1996) reported a prevalence of 22% in adults
04/08/23 14
Current Concepts During the last four decades, asthma has been
considered primarily as a dse of airway smooth muscle.
But, based on the National Institute of Health guidelines (1997) concept shifted to airway inflammation Release of inflammatory mediators from eosinophils and
masts cells – persistent bronchial inflammation – structural abn:
fibrosis, inc sm muscle mass & mucus glands, inc epithelial shedding and thickening of the reticular
basement membrane, fiibronectin deposition in the subepithelial layer
04/08/23 15
Asthma Definition: A chronic reactive airway disorder
that produces episodic reversible airway obstruction via bronchospasm, increased mucous secretions and mucosal edema
Classifications: Extrinsic Asthma (atopic asthma)
Results from sensitivity to specific external allergens Intrinsic Asthma (non-atopic asthma)
No extrinsic substance can be identified; usually preceded by severe respiratory infection
04/08/23 16
It causes recurring episodes of wheezing, breathlessness, chest tightness, and coughing particularly at night or in the early morning
Common risk factors: Domestic dust mites, Animals with fur, Coakroach Pollens and molds, Occupational irritants Tobacco smoke, Respiratory (viral) infections Exercise, Strong emotional expressions Chemical irritants and drugs
04/08/23 17
Severity can be intermittent, or it can be persistently mild, moderate or severe; treatment decisions are based on severity
Should take into account stepwise approach to pharmacologic treatment to achieve and maintain control of asthma
Attacks are episodic, but airways inflammation is chronically present
Medications should be taken daily to maintain to control symptoms, improve lung function and prevent attacks
Asthma requires a partnership between the patient and health care professional
04/08/23 18
Current Concepts on Asthma as a Disease Airway thickening by 50-300% of
normal Leading to airway remodelling Resulting to:
Inc airway hyperresponsiveness Non-reversibility of airway obstruction and
residual obstruction after bronchodilator and anti-inflammatory therapy
Accelerated dec in FEV in some asthmatic patients
04/08/23 19
Diagnosis of Asthma
History, PE, and objective measurements of variable airflow obstruction and/or bronchial hyperresponsiveness
But, Hx and PE may not be reliable at times. Thus, an objective measure is needed to dx
accurately Screening strats: Hx, PE Strats for confirmation: FEV1, PEFR, Airway
hyperresponsiveness
04/08/23 20
History Asthma should be suspected in any
patient who has any of the following: Cough: worsens at night Wheeze Difficulty in breathing Chest tightness
Dxc accuracy increases as more symptoms are present
Dx is strengthened if: (+) hx of waxing and waning of symptoms provoked
usu by allergens, irritants, exercise, viral infection; (+)FHx; improvement after use of anti-asthma meds
04/08/23 21
Physical Examination
Note that PE may be normal in px with asthma
Wheezes are characteristic but not specific for asthma
Thus, px may have normal auscultation but has significant airway obstruction
A better parameter for significant airway obstruction: prolonged forced expiratory time (6 secs or more) = correlates with moderate to severe a.o.
04/08/23 22
Forced Expiratory Volume in 1 second (FEV 1)
Spirometry to document airflow obstruction in asthma
Variable airflow obstruction documented via: Spontaneous variability in FEV Improvement noted 15 mins after inhaled B2-
agonist administration
Significant: 12% (200ml at least) improvement in FEV1
Or: at least 20% improvement in FEV1 after a week with or without oral steroids, or after 2 wks of inhaled steroids
04/08/23 23
In the absence of spirometry, home measurement of PEF may be used +
Response to B2-agonist PEF variability is computed as
mean percentage difference b/w post-bronchodilator pm value & pre-bronchodilator am value x several wks or
Minimum am pre-bronchodilator PEF x 1wk (Min%/ Max)
asthma if variability of 20% or more
Peak Expiratory Flow Rate
04/08/23 24
Peak Expiratory Flow Rate
May also be used in clinics, ER and hospital If with an improvement of 20% or more in the
PEFR 15 mins after administration of 200-400ug of inhaled salbutamol or other equivalent, may be used as indicator of asthma
PEFR is more suited for monitoring rather than for diagnosis
Thus, it is more of an adjunct to spirometry; not as substitute
04/08/23 25
Airway Hyperresponsiveness
If asthma is still suspected in patients with normal FEV1
Documentation via: Methacholine or histamine inhalation
challenge Best to use if the pretest probability of
having asthma based on sx is 30-70% A negative test is more reliable in excluding
a dx of asthma
04/08/23 26
Asthma Classification
According to Etiology And severity (clinical condition on
presentation whether the patient is in acute state or chronic state)
Etiology: limited because no environmental cause can be identified A rigorous search for a SPECIFIC
environmental cause should be part of the initial assessment
04/08/23 27
Severity: Acute state (in exacerbation) Chronic state
04/08/23 28
New Classification of Chronic Asthma SeverityParameter S E V E R I T Y
Persistent
Intermittent Mild-Moderate
Severe
Daytime Sx less than wkly wkly daily
Nocturnal awakening
Less than monthly
Monthly- wkly
nightly
Rescue B2 use
Less than wkly Wkly-daily Several times daily
PEF or FEV More than 80% 60-80 Less than 60
Control Prn B2 agonist LABA + ICS ICS+LABA+ OCS
04/08/23 29
Six-Part Program to Manage and Control Asthma
1) Educate patients to develop a partnership in asthma care
2) Assess and monitor asthma severity
3) Avoid exposure to risk factors
4) Establish individual medication plans for long-term management in children and adults
5) Establish individual plans to manage asthma attacks
6) Provide regular follow-up care
04/08/23 30
Goals for successful management of asthma Minimal or no symptoms, including nighttime
symptoms Minimal asthma episodes or attacks No emergency visits to physicians or hospitals Minimal need for reliever medications No limitations on physical activities and exercise Nearly normal lung function Minimal or no side effects from medications
04/08/23 31
Part 1: Educate Patients to develop a partnership in asthma care Patient can learn to:
avoid risks factors and take medications correctly Understand the difference between “controllers”
and “reliever” medications Monitor their status using symptoms and if
available PEF Recognize signs that asthma is worsening and
take action Seek medical help as appropriate
04/08/23 32
Part 1: Educate Patients to develop a partnership in asthma care Asthma management plans should cover:
Prevention steps for long-term control: asthma risk factors to avoid & daily medication to take
Action steps to stop attacks
Ongoing education presented at every patient visit, is the key to success in all aspects of asthma management
04/08/23 33
Part 2: Assess and monitor Asthma Severity Monitoring includes review of symptoms and
if possible measurement of lung function Regular visits (1-6 months interval) even after
control of asthma is established Addressing patient’s concern, fears and
expectations related to asthma to ensure compliance and adherence to asthma management
04/08/23 34
Part 3: Avoid Exposure to Risk Factors Specific Immunotherapy, directed at
treating an underlying allergy to grass and other pollen, domestic mites, animal dander, or alternaria, may be considered when avoiding allergens is not possible or appropriate medications fail to control asthma symptoms.
Primary prevention of asthma is not yet possible, but promising leads are being actively investigated
04/08/23 35
Part 4: Establish Individual Medication Plans for Long-term Management in Children and Adults Stepwise Approach
Used to classify asthma and severity and guide treatment
The number and frequency of medications increase (step up) as the need for asthma therapy increases, and decreases (step down) when asthma is under control
04/08/23 36
Gain Control First approach: Establish control promptly with a
high level of therapy and then step down.
Ex: Add a short course oral glucocorticosteroid and /or a higher dose if inhaled glucocorticosteroid + long-acting B2 agonist to the therapy that corresponds with the patient’s level of asthma severity
Second approach: Start treatment at the step most appropriate to the level of asthma severity and step up if necessary
04/08/23 37
Step up: if control is not achieved and sustained. Improvement should be achieved within 1 month. Review patient’s medication technique, compliance and avoidance of risk factors
Step down: if control is sustained for at least 3 months; follow a gradual stepwise reduction in treatment. Goal is to decrease treatment to the least medication necessary to maintain control
04/08/23 38
Review treatment every 3 to 6months once asthma is under control
Consult with an asthma specialist when other conditions complicate asthma (sinusitis), the patient does not respond to therapy, or treatment at 3 or 4 required
04/08/23 39
Acute Asthma ManagementInitial Assessment
History, PE, PEF or FEV1
Initial TherapyBronchodilators; O2 if needed
Incomplete/Poor Response
Add SystemicGlucocorticosteroid
Good Response
Observe for at least 1 hour
If Stable Discharge Good Response Poor Response
Admit to Hospital
Respiratory Failure
Admit toICU
04/08/23 40
Stepwise approach to long-term management of asthma Criteria in the choice of treatment:
Severity of asthma Current treatment Pharmacological properties Availability of the various forms of asthma
treatment Economic considerations Cultural preference Differing health care system
04/08/23 41
Part 5: Establish Individual Plans to Manage Asthma attacks Mild attacks can be treated at home if patient
is prepared and has a personal asthma management plan that includes action steps
Moderate attacks may require, and severe attacks usually require, care in a clinic or hospital
Monitor response to treatment Evaluate symptoms, if possible, peak flow In hospital: assess O2 saturation, consider arterial
blood gas measurement, exhaustion, etc
04/08/23 42
Part 6: Provide Regular Follow-up Care Once asthma control is established, regular
follow-up visits, at 1-6 months intervals as appropriate
During visits, monitor and review treatment plans, medications and level of asthma control
04/08/23 43
04/08/23 44
04/08/23 45
Goal
Morbidity and Mortality from lifestyle-related diseases are reduced and the quality of life of those who are suffering from such diseases is improved.
04/08/23 46
National Objective Mortality from degenerative or lifestyle-
related diseases is reduced. Indicator
Mortality rate from COPD per 100,000 population
Target Less than 20.8 deaths per 100,000
population (PHS, 2000)
04/08/23 47
Strategic Thrusts for 2005 to 2010
Implement sound, long-term and sustained Healthy Lifestyle promotion programs
Promote information, education and advocacy campaigns
Translate and implement provisions of the tobacco laws as local ordinances and develop community infrastructure supportive of healthy lifestyle
Pursue training of clinicians and other frontline healthcare providers
Manage risk behaviors and risk factors Strengthen networking and collaboration Support and implement financial risk protection
measures
04/08/23 48
Definition
COPD is a disease state characterized by airflow limitation that is not fully reversible.
The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases
Diagnosis should be considered in any patient who has symptoms of cough, sputum production, or dyspnea, and/or history of exposure to risk factors for the disease.
04/08/23 49
Components of COPD that may coexistwith Chronic Bronchitis Emphysema Small airway disease ( Obstructive
Bronchiolitis) Chronic Asthma with only partial reversibility
04/08/23 50
Risk Factors
Smoking – 85% Coal Isocyanates Silica Cadmium Other dust
04/08/23 51
Classification of Severity of COPD Stage 0: At Risk
Normal spirometry Chronic symptoms (cough, sputum production)
Stage I: Mild COPD FEV1/FVC < 70% FEV1 80% predicted With or without chronic symptoms (cough, sputum
production)
04/08/23 52
Stage II Moderate FEV1/FVC ,70%; 50% FEV1<80% predicted w/ or w/o chromic symptoms
Stage III Severe COPD FEV1/FVC ,70%; 30% FEV1<50% predicted w/ or w/o chromic symptoms
Severe IV Severe COPD FEV1/FVC ,70%; 30% FEV1<50% predicted Plus chronic respiratory failure
04/08/23 53
Stages of COPD ( Australian New Zealand Guidelines)COPDXStage Postbronchodilator FEV1
Mild 60-80% predicted
Moderate 40-59% predicted
Severe < 40% predicted
04/08/23 54
EPIDEMIOLOGY Prevalence and morbidity data greatly
underestimate the total burden of COPD because the disease is usually not diagnosed until it is clinically apparent and moderately advanced
Mortality data also underestimate COPD as a cause of death because the disease is more likely to be cited as a contributory than as an underlying cause of death, or may not be cited at all
04/08/23 55
lobal Initiative for Chronic
bstructive
ung
isease
lobal Initiative for Chronic
bstructive
ung
isease
G
OLD
G
OLD
04/08/23 56
GOLD Structure
GOLD Executive CommitteeSonia Buist, MD – Chair
Roberto Rodriguez-Roisin, MD – Co-Chair
Science Committee
Klaus Rabe, MD, PhD - Chair
Science Committee
Klaus Rabe, MD, PhD - Chair
Dissemination/ImplementationTask Group
Christine Jenkins, MD - Chair
Dissemination/ImplementationTask Group
Christine Jenkins, MD - Chair
04/08/23 57
GOLD Executive Committee
S. Buist, Chair, US
A. Anzueto, US ATS
P. Calverley, UK
T. DeGuia, Philippines
Y. Fukuchi, Japan APSR
C. Jenkins, Australia
J. Kiley, US NHLBI
A. Kocabas, Turkey
N. Khaltaev, Switzerland WHO
M. Lopez, Uruguay ALAT
E. Nizankowska, Poland
K. Rabe, Netherlands
R. Rodriguez-Roisin, Spain
T. van der Molen, Netherlands
C. Van Weel, Netherlands WONCA
04/08/23 58
GOLD Science Committee
K. Rabe, Chair A. Agusti, A. AnzuetoP. BarnesS. BuistP. Calverley
M. DecramerY. Fukuchi P. JonesR. Rodriguez-RoisinJ. VestboJ. Zielinski
04/08/23 59
Evidence Category
Sources of Evidence
A Randomized controlled trials (RCTs). Rich body of data
B Randomized controlled trials(RCTs). Limited body of data
C Nonrandomized trialsObservational studies.
D Panel consensus judgment
Description of Levels of Evidence
04/08/23 60
GOLD Structure
GOLD Executive CommitteeSonia Buist, MD – Chair
Roberto Rodriguez-Roisin, MD – Co-Chair
Science Committee
Klaus Rabe, MD, PhD - Chair
Science Committee
Klaus Rabe, MD, PhD - Chair
Dissemination/ImplementationTask Group
Christine Jenkins, MD - Chair
Dissemination/ImplementationTask Group
Christine Jenkins, MD - Chair
GOLD National Leaders - GNL
04/08/23 61
United StatesUnited States
United Kingdom
ArgentinaArgentina
AustraliaAustraliaBrazilBrazil Austria
CanadaCanada
Chile
Belgium
ChinaChina
DenmarkDenmark
ColumbiaColumbia
CroatiaCroatia
EgyptEgypt
Germany
Greece
IrelandIreland
ItalyItaly
SyriaSyria
Hong Kong ROC
Japan
IcelandIndiaIndia
KoreaKorea
KyrgyzstanUruguayUruguay
MoldovaMoldova
NepalNepal
Macedonia
Malta
Netherlands
New Zealand
PolandPoland
NorwayNorway
Portugal
GeorgiaGeorgia
Romania
Russia
SingaporeSlovakia
Slovenia Saudi ArabiaSaudi Arabia
South AfricaSouth Africa
Spain
SwedenSweden
ThailandThailand
SwitzerlandSwitzerland
UkraineUkraine
United Arab EmiratesUnited Arab Emirates
Taiwan ROC
VenezuelaVenezuela
Vietnam
Peru
Yugoslavia
Albania
Bangladesh
France
Mexico
Turkey Czech Republic
Pakistan
Israel
GOLD National Leaders
Philippines
04/08/23 62
GOLD Website Address
http://www.goldcopd.org
04/08/23 63
GOLD Objectives
Increase awareness of COPD among health professionals, health authorities, and the general public.
Improve diagnosis, management and prevention of COPD.
Stimulate research in COPD.
04/08/23 64
Global Strategy for Diagnosis, Management and Prevention of COPD
Global Strategy for Diagnosis, Management and Prevention of COPD
Definition, Classification
Burden of COPD Risk Factors Pathogenesis,
Pathology, Pathophysiology
Management Practical
Considerations
Definition, Classification
Burden of COPD Risk Factors Pathogenesis,
Pathology, Pathophysiology
Management Practical
Considerations
04/08/23 65
Definition of COPD
COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual patients.
Its pulmonary component is characterized by airflow limitation that is not fully reversible.
The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases.
04/08/23 66
Classification of COPD Severity
by SpirometryStage I: Mild FEV1/FVC < 0.70
FEV1 > 80% predicted
Stage II: Moderate FEV1/FVC < 0.70 50% < FEV1 < 80% predicted
Stage III: Severe FEV1/FVC < 0.70 30% < FEV1 < 50% predicted
Stage IV: Very Severe FEV1/FVC < 0.70 FEV1 < 30% predicted or
FEV1 < 50% predicted plus chronic respiratory failure
04/08/23 67
“At Risk” for COPD
COPD includes four stages of severity classified by spirometry.
A fifth category--Stage 0: At Risk--that appeared in the 2001 report is no longer included as a stage of COPD, as there is incomplete evidence that the individuals who meet the definition of “At Risk” (chronic cough and sputum production, normal spirometry) necessarily progress on to Stage I: Mild COPD.
The public health message is that chronic cough and sputum are not normal remains important - their presence should trigger a search for underlying cause(s).
04/08/23 68
Global Strategy for Diagnosis, Management and Prevention of COPD
Global Strategy for Diagnosis, Management and Prevention of COPD
Definition, Classification
Burden of COPD Risk Factors Pathogenesis,
Pathology, Pathophysiology
Management Practical
Considerations
Definition, Classification
Burden of COPD Risk Factors Pathogenesis,
Pathology, Pathophysiology
Management Practical
Considerations
04/08/23 69
Burden of COPD: Key Points
COPD is a leading cause of morbidity and mortality worldwide and results in an economic and social burden that is both substantial and increasing.
COPD prevalence, morbidity, and mortality vary across countries and across different groups within countries.
The burden of COPD is projected to increase in the coming decades due to continued exposure to COPD risk factors and the changing age structure of the world’s population.
04/08/23 70
Burden of COPD: Prevalence
Many sources of variation can affect estimates of COPD prevalence, including e.g., sampling methods, response rates and quality of spirometry.
Data are emerging to provide evidence that prevalence of Stage I: Mild COPD and higher is appreciably higher in:
- smokers and ex-smokers - people over 40 years of age- males
04/08/23 71
COPD Prevalence Study in Latin America
The prevalence of post-bronchodilator FEV1/FVC < 0.70 increases steeply with age in 5 Latin American Cities
Source: Menezes AM et al. Lancet 2005
04/08/23 72
Burden of COPD: Mortality
COPD is a leading cause of mortality worldwide and projected to increase in the next several decades.
COPD mortality trends generally track several decades behind smoking trends.
In the US and Canada, COPD mortality for both men and women have been increasing.
In the US in 2000, the number of COPD deaths was greater among women than men.
04/08/23 73
Percent Change in Age-Adjusted Death Rates, U.S., 1965-1998
Percent Change in Age-Adjusted Death Rates, U.S., 1965-1998
00
0.50.5
1.01.0
1.51.5
2.02.0
2.52.5
3.03.0
Proportion of 1965 Rate Proportion of 1965 Rate
1965 - 19981965 - 1998 1965 - 19981965 - 1998 1965 - 19981965 - 1998 1965 - 19981965 - 1998 1965 - 19981965 - 1998
–59%–59% –64%–64% –35%–35% +163%+163% –7%–7%
CoronaryHeart
Disease
CoronaryHeart
Disease
StrokeStroke Other CVDOther CVD COPDCOPD All OtherCauses
All OtherCauses
Source: NHLBI/NIH/DHHSSource: NHLBI/NIH/DHHS
04/08/23 74
Of the six leading causes of death in the United States, only COPD has been increasing steadily since 1970
Source: Jemal A. et al. JAMA 2005
04/08/23 75
COPD Mortality by Gender,U.S., 1980-2000
0
10
20
30
40
50
60
70
1980 1985 1990 1995 2000
Men
Women
Num
ber
Death
s x
100
0N
um
ber
Death
s x
100
0
Source: US Centers for Disease Control and Prevention, 2002
04/08/23 76
Global Strategy for Diagnosis, Management and Prevention of COPD
Global Strategy for Diagnosis, Management and Prevention of COPD
Definition, Classification
Burden of COPD Risk Factors Pathogenesis,
Pathology, Pathophysiology
Management Practical
Considerations
Definition, Classification
Burden of COPD Risk Factors Pathogenesis,
Pathology, Pathophysiology
Management Practical
Considerations
04/08/23 77
Risk Factors for COPD
Lung growth and development
Oxidative stress
Gender
Age
Respiratory infections
Socioeconomic status
Nutrition
Comorbidities
Genes
Exposure to particles
●Tobacco smoke
●Occupational dusts, organic and inorganic
●Indoor air pollution from heating and cooking with biomass in poorly ventilated dwellings
●Outdoor air pollution
04/08/23 78
Risk Factors for COPD
NutritionNutrition
InfectionsInfections
Socio-economic Socio-economic statusstatus
Aging PopulationsAging Populations
04/08/23 79
Global Strategy for Diagnosis, Management and Prevention of COPD
Global Strategy for Diagnosis, Management and Prevention of COPD
Definition, Classification
Burden of COPD Risk Factors Pathogenesis,
Pathology, Pathophysiology
Management Practical
Considerations
Definition, Classification
Burden of COPD Risk Factors Pathogenesis,
Pathology, Pathophysiology
Management Practical
Considerations
04/08/23 80
04/08/23 81
Mucus gland hyperplasia
Goblet cellhyperplasia
Mucus hypersecretion Neutrophils in sputum
Squamous metaplasia of epithelium
↑ Macrophages
No basement membrane thickening
Little increase in airway smooth muscle
↑ CD8+ lymphocytes
Changes in Large Airways of COPD Patients
Changes in Large Airways of COPD Patients
Source: Peter J. Barnes, MD
04/08/23 82
Alveolar wall destruction
Loss of elasticity
Destruction of pulmonarycapillary bed
↑ Inflammatory cells macrophages, CD8+ lymphocytes
Changes in the Lung Parenchyma in COPD Patients
Source: Peter J. Barnes, MD
04/08/23 83
Endothelial dysfunction
Intimal hyperplasia
Smooth muscle hyperplasia
↑ Inflammatory cells (macrophages, CD8+ lymphocytes)
Changes in Pulmonary Arteries in COPD Patients
Source: Peter J. Barnes, MD
04/08/23 84
LUNG INFLAMMATIONLUNG INFLAMMATION
COPD PATHOLOGYCOPD PATHOLOGY
OxidativeOxidativestressstress ProteinasesProteinases
Repair Repair mechanismsmechanisms
Anti-proteinasesAnti-proteinasesAnti-oxidantsAnti-oxidants
Host factorsAmplifying mechanisms
Cigarette smokeCigarette smokeBiomass particlesBiomass particles
ParticulatesParticulates
Pathogenesis of COPD
Source: Peter J. Barnes, MD
04/08/23 85
Cigarette smoke Cigarette smoke (and other irritants)(and other irritants)
PROTEASES PROTEASES Neutrophil elastaseNeutrophil elastaseCathepsinsCathepsinsMMPsMMPs
Alveolar wall destructionAlveolar wall destruction(Emphysema)(Emphysema)
Mucus hypersecretionMucus hypersecretion
CD8CD8+ +
lymphocytelymphocyte
Alveolar Alveolar macrophagemacrophage
EpithelialEpithelialcellscells
FibrosisFibrosis(Obstructive(Obstructivebronchiolitis)bronchiolitis)
FibroblastFibroblast
MonocyteMonocyteNeutrophilNeutrophil
Chemotactic factorsChemotactic factors
Inflammatory Cells Involved in COPD
Source: Peter J. Barnes, MD
04/08/23 86
Anti-proteases
SLPI 1-AT
Proteolysis
OO22--, H, H220022
OHOH.., ONOO, ONOO--
Mucus secretion
Plasma leak Bronchoconstriction
NF-NF-BB
IL-8IL-8
NeutrophilNeutrophilrecruitmentrecruitment
TNF-TNF-
IsoprostanesIsoprostanes
↓ ↓ HDAC2HDAC2
↑↑InflammationInflammationSteroidSteroid
resistanceresistance
Macrophage NeutrophilOxidative Stress in COPD
Source: Peter J. Barnes, MD
04/08/23 87
Differences in Inflammation and its Consequences: Asthma and COPD
YYYYYY
Mast cellMast cell
CD4+ cellCD4+ cell(Th2)(Th2)
EosinophilEosinophil
AllergensAllergens
Ep cellsEp cells
ASTHMAASTHMA
BronchoconstrictiBronchoconstrictionon
AHRAHR
Alv macrophageAlv macrophage Ep cellsEp cells
CD8+ cellCD8+ cell(Tc1)(Tc1)
NeutrophilNeutrophil
Cigarette smokeCigarette smoke
Small airway narrowingSmall airway narrowingAlveolar destructionAlveolar destruction
COPDCOPD
Reversible IrreversibleAirflow LimitationAirflow Limitation
Source: Peter J. Barnes, MD
04/08/23 88
NormalNormalInspiration
Expiration
alveolar attachments
Mild/moderateMild/moderateCOPD COPD
loss of elasticity
Severe Severe COPD COPD
loss of alveolar attachments
closure
small small airwayairway
Dyspnea↓ Exercise capacity
Air trappingAir trappingHyperinflationHyperinflation
↓ ↓ HealthHealthstatusstatus
Air Trapping in COPD
Source: Peter J. Barnes, MD
04/08/23 89
Chronic hypoxiaChronic hypoxia
Pulmonary vasoconstrictionPulmonary vasoconstriction
MuscularizationMuscularization
Intimal Intimal hyperplasiahyperplasia
FibrosisFibrosis
ObliterationObliteration
Pulmonary hypertensionPulmonary hypertension
Cor pulmonaleCor pulmonale
Death
EdemaEdema
Pulmonary Hypertension in COPD
Source: Peter J. Barnes, MD
04/08/23 90
Macrophages
TNF- IL-8 IL-6
Bacteria Viruses Non-infective Pollutants
Epithelial cells
Oxidative stressOxidative stress
Neutrophils
Inflammation in COPD Exacerbations
Source: Peter J. Barnes, MD
04/08/23 91
Global Strategy for Diagnosis, Management and Prevention of COPD
Global Strategy for Diagnosis, Management and Prevention of COPD
Definition, Classification
Burden of COPD Risk Factors Pathogenesis,
Pathology, Pathophysiology
Management Practical
Considerations
Definition, Classification
Burden of COPD Risk Factors Pathogenesis,
Pathology, Pathophysiology
Management Practical
Considerations
04/08/23 92
Four Components of COPD ManagementFour Components of COPD Management
1. Assess and monitor disease
2. Reduce risk factors
3. Manage stable COPD Education Pharmacologic Non-pharmacologic
4. Manage exacerbations
1. Assess and monitor disease
2. Reduce risk factors
3. Manage stable COPD Education Pharmacologic Non-pharmacologic
4. Manage exacerbations
04/08/23 93
• Relieve symptoms • Prevent disease progression• Improve exercise tolerance• Improve health status• Prevent and treat complications• Prevent and treat exacerbations• Reduce mortality
GOALS of COPD MANAGEMENTVARYING EMPHASIS WITH DIFFERING SEVERITY
04/08/23 94
Four Components of COPD ManagementFour Components of COPD Management
1. Assess and monitor disease
2. Reduce risk factors
3. Manage stable COPD Education Pharmacologic Non-pharmacologic
4. Manage exacerbations
1. Assess and monitor disease
2. Reduce risk factors
3. Manage stable COPD Education Pharmacologic Non-pharmacologic
4. Manage exacerbations
04/08/23 95
Management of Stable COPD
Assess and Monitor COPD: Key PointsA clinical diagnosis of COPD should be
considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease.
The diagnosis should be confirmed by spirometry. A post-bronchodilator FEV1/FVC < 0.70 confirms the presence of airflow limitation that is not fully reversible.
Comorbidities are common in COPD and should be actively identified.
04/08/23 96
SYMPTOMScoughcough
sputumsputumshortness of breathshortness of breath
EXPOSURE TO RISKFACTORS
tobaccotobaccooccupationoccupation
indoor/outdoor pollutionindoor/outdoor pollution
SPIROMETRYSPIROMETRY
Diagnosis of COPDDiagnosis of COPD
04/08/23 97
Management of Stable COPD
Assess and Monitor COPD: Spirometry
Spirometry should be performed after the administration of an adequate dose of a short-
acting inhaled bronchodilator to minimize variability.
A post-bronchodilator FEV1/FVC < 0.70 confirms the presence of airflow limitation that is not fully reversible.
Where possible, values should be compared to age-related normal values to avoid overdiagnosis of COPD in the elderly.
04/08/23 98
Spirometry: Normal and Patients with COPD
04/08/23 99
Differential Diagnosis: Differential Diagnosis: COPD and AsthmaCOPD and Asthma
COPD ASTHMA
• Onset in mid-life
• Symptoms slowly progressive
• Long smoking history
• Dyspnea during exercise
• Largely irreversible airflow limitation
• Onset early in life (often childhood)
• Symptoms vary from day to day
• Symptoms at night/early morning
• Allergy, rhinitis, and/or eczema also present
• Family history of asthma
• Largely reversible airflow limitation
04/08/23 100
COPD and Co-Morbidities
COPD patients are at increased risk for: • Myocardial infarction, angina• Osteoporosis• Respiratory infection• Depression• Diabetes• Lung cancer
04/08/23 101
COPD and Co-Morbidities
COPD has significant extrapulmonary
(systemic) effects including:
• Weight loss
• Nutritional abnormalities
• Skeletal muscle dysfunction
04/08/23 102
Four Components of COPD Management
1. Assess and monitor disease
2. Reduce risk factors
3. Manage stable COPD Education Pharmacologic Non-pharmacologic
4. Manage exacerbations
1. Assess and monitor disease
2. Reduce risk factors
3. Manage stable COPD Education Pharmacologic Non-pharmacologic
4. Manage exacerbations
04/08/23 103
Management of Stable COPD
Reduce Risk Factors: Key PointsReduction of total personal exposure to
tobacco smoke, occupational dusts and chemicals, and indoor and outdoor air pollutants are important goals to prevent the onset and progression of COPD.
Smoking cessation is the single most effective — and cost effective — intervention in most people to reduce the risk of developing COPD and stop its progression (Evidence A).
04/08/23 104
Brief Strategies to Help the Patient Willing to Quit Smoking
• ASK Systematically identify all tobacco users at every visit.
• ADVISE Strongly urge all tobacco users to quit.
• ASSESS Determine willingness to make a quit attempt.
• ASSIST Aid the patient in quitting.
• ARRANGE Schedule follow-up contact.
04/08/23 105
Management of Stable COPD
Reduce Risk Factors: Smoking Cessation Counseling delivered by physicians and
other health professionals significantly increases quit rates over self-initiated strategies. Even a brief
(3-minute) period of counseling to urge a smoker to quit results in smoking cessation rates of 5-10%.
Numerous effective pharmacotherapies for smoking cessation are available and pharmacotherapy is recommended when counseling is not sufficient to help patients quit smoking.
04/08/23 106
Management of Stable COPD
Reduce Risk Factors: Indoor/Outdoor Air Pollution
Reducing the risk from indoor and outdoor air pollution is feasible and requires a combination of public policy and protective steps taken by individual patients.
Reduction of exposure to smoke from biomass fuel, particularly among women and children, is a crucial goal to reduce the prevalence of COPD worldwide.
04/08/23 107
Four Components of COPD Management
1. Assess and monitor disease
2. Reduce risk factors
3. Manage stable COPD Education Pharmacologic Non-pharmacologic
4. Manage exacerbations
1. Assess and monitor disease
2. Reduce risk factors
3. Manage stable COPD Education Pharmacologic Non-pharmacologic
4. Manage exacerbations
04/08/23 108
Management of Stable COPD
Manage Stable COPD: Key Points The overall approach to managing stable COPD
should be individualized to address symptoms and improve quality of life.
For patients with COPD, health education plays an important role in smoking cessation (Evidence A) and can also play a role in improving skills, ability to cope with illness and health status.
None of the existing medications for COPD have been shown to modify the long-term decline in lung function that is the hallmark of this disease (Evidence A). Therefore, pharmacotherapy for COPD is used to decrease symptoms and/or complications.
04/08/23 109
Management of Stable COPD
Pharmacotherapy: Bronchodilators Bronchodilator medications are central to the
symptomatic management of COPD (Evidence A). They are given on an as-needed basis or on a
regular basis to prevent or reduce symptoms and exacerbations.
The principal bronchodilator treatments are ß2-agonists, anticholinergics, and methylxanthines used singly or in combination (Evidence A).
Regular treatment with long-acting bronchodilators is more effective and convenient than treatment with short-acting bronchodilators (Evidence A).
04/08/23 110
Management of Stable COPD
Pharmacotherapy: Glucocorticosteroids The addition of regular treatment with
inhaled glucocorticosteroids to bronchodilator
treatment is appropriate for symptomatic COPD patients with an FEV1 < 50% predicted (Stage III: Severe COPD and Stage IV: Very Severe COPD) and repeated exacerbations (Evidence A).
An inhaled glucocorticosteroid combined with a long-acting ß2-agonist is more effective than the individual components (Evidence A).
04/08/23 111
Management of Stable COPD
Pharmacotherapy: Glucocorticosteroids The dose-response relationships and
long-term safety of inhaled glucocorticosteroids in COPD are not known.
Chronic treatment with systemic glucocorticosteroids should be avoided because of an unfavorable benefit-to-risk ratio (Evidence A).
04/08/23 112
Management of Stable COPD
Pharmacotherapy: Vaccines
In COPD patients influenza vaccines can reduce serious illness (Evidence A).
Pneumococcal polysaccharide vaccine is recommended for COPD patients 65 years and older and for COPD patients younger than age 65 with an FEV1 < 40% predicted (Evidence B).
04/08/23 113
Management of Stable COPD
All Stages of Disease Severity Avoidance of risk factors
- smoking cessation
- reduction of indoor pollution
- reduction of occupational exposure
Influenza vaccination
04/08/23 114
IV: Very Severe III: Severe II: Moderate I: Mild
Therapy at Each Stage of COPD
FEV1/FVC < 70%
FEV1 > 80% predicted
FEV1/FVC < 70%
50% < FEV1 < 80% predicted
FEV1/FVC < 70%
30% < FEV1 < 50% predicted
FEV1/FVC < 70%
FEV1 < 30% predicted
or FEV1 < 50% predicted plus chronic respiratory failure
Add regular treatment with one or more long-acting bronchodilators (when needed); Add rehabilitation
Add inhaled glucocorticosteroids if repeated exacerbations
Active reduction of risk factor(s); influenza vaccinationAdd short-acting bronchodilator (when needed)
Add long term oxygen if chronic respiratory failure. Consider surgical treatments
04/08/23 115
Management of Stable COPD
Other Pharmacologic Treatments Antibiotics: Only used to treat
infectious exacerbations of COPD
Antioxidant agents: No effect of n-acetylcysteine on frequency of exacerbations, except in patients not treated with inhaled glucocorticosteroids
Mucolytic agents, Antitussives, Vasodilators: Not recommended in stable COPD
04/08/23 116
Management of Stable COPD
Non-Pharmacologic Treatments
Rehabilitation: All COPD patients benefit from exercise training programs, improving with respect to both exercise tolerance and symptoms of dyspnea and fatigue (Evidence A).
Oxygen Therapy: The long-term administration of oxygen (> 15 hours per day) to patients with chronic respiratory failure has been shown to increase survival (Evidence A).
04/08/23 117
Four Components of COPD Management
1. Assess and monitor disease
2. Reduce risk factors
3. Manage stable COPD Education Pharmacologic Non-pharmacologic
4. Manage exacerbations
1. Assess and monitor disease
2. Reduce risk factors
3. Manage stable COPD Education Pharmacologic Non-pharmacologic
4. Manage exacerbations
Revised 2006
04/08/23 118
Management COPD Exacerbations
Key Points
An exacerbation of COPD is defined as:
“An event in the natural course of the disease characterized by a change in the patient’s baseline dyspnea, cough, and/or sputum that is beyond normal day-to-day variations, is acute in onset, and may warrant a change in regular medication in a patient with underlying COPD.”
04/08/23 119
Management COPD Exacerbations
Key PointsThe most common causes of an
exacerbation are infection of the tracheobronchial tree and air pollution, but the cause of about one-third of severe exacerbations cannot be identified (Evidence B).
Patients experiencing COPD exacerbations with clinical signs of airway infection (e.g., increased sputum purulence) may benefit from antibiotic treatment (Evidence B).
04/08/23 120
Manage COPD Exacerbations
Key Points
Inhaled bronchodilators
(particularly inhaled ß2-agonists
with or without anticholinergics)
and oral glucocortico- steroids
are effective treatments for
exacerbations of COPD (Evidence
A).
04/08/23 121
Management COPD Exacerbations
Key Points
Noninvasive mechanical ventilation in exacerbations improves respiratory acidosis, increases pH, decreases the need for endotracheal intubation, and reduces PaCO2, respiratory rate, severity of breathlessness, the length of hospital stay, and mortality (Evidence A).
Medications and education to help prevent future exacerbations should be considered as part of follow-up, as exacerbations affect the quality of life and prognosis of patients with COPD.
04/08/23 122
Global Strategy for Diagnosis, Management and Prevention of COPD
Definition, Classification
Burden of COPD Risk Factors Pathogenesis,
Pathology, Pathophysiology
Management Practical
Considerations
Definition, Classification
Burden of COPD Risk Factors Pathogenesis,
Pathology, Pathophysiology
Management Practical
Considerations
04/08/23 123
Translating COPD Guidelines into Primary Care
KEY POINTS
Better dissemination of COPD guidelines and their effective implementation in a variety of health care settings is urgently required.
In many countries, primary care practitioners treat the vast majority of patients with COPD and may be actively involved in public health campaigns and in bringing messages about reducing exposure to risk factors to both patients and the public.
04/08/23 124
Translating COPD Guidelines into Primary Care
KEY POINTS
Spirometric confirmation is a key component of the diagnosis of COPD and primary care practitioners should have access to high quality spirometry.
Older patients frequently have multiple chronic health conditions. Comorbidities can magnify the impact of COPD on a patient’s health status, and can complicate the management of COPD.
04/08/23 125
Global Strategy for Diagnosis, Management and Prevention of COPDSUMMARY
Definition, Classification
Burden of COPD Risk Factors Pathogenesis,
Pathology, Pathophysiology
Management Practical
Considerations
Definition, Classification
Burden of COPD Risk Factors Pathogenesis,
Pathology, Pathophysiology
Management Practical
Considerations
04/08/23 126
Global Strategy for Diagnosis, Management and Prevention of COPD: Summary
COPD is increasing in prevalence in many countries of the world.
COPD is treatable and preventable.
The GOLD program offers a strategy to identify patients and to treat them according to the best medications available.
04/08/23 127
COPD can be prevented by avoidance of risk factors, the most notable being tobacco smoke.
Patients with COPD have multiple other conditions (comorbidities) that must be taken into consideration.
GOLD has developed a global network to raise awareness of COPD and disseminate information on diagnosis and treatment.
Global Strategy for Diagnosis, Management and Prevention of COPD:
Summary
04/08/23 128
WORLD COPD DAYNovember 14, 2007
WORLD COPD DAYNovember 14, 2007
Raising COPD Awareness WorldwideRaising COPD Awareness Worldwide
04/08/23 129
Global Initiative for Chronic Obstructive Lung Disease (GOLD) Conducted in collaboration with the US National
Heart Lung and Blood Institute (NHLBI) and WHO. Goal:
To increase awareness of COPD and decrease morbidity and mortality from the disease
Aims : to improve prevention and management of COPD through
a concerted worldwide effort of people involved in all facets of health care and health care policy, and
to encourage a renewed research interest in this extremely prevalent disease
04/08/23 130
GOLD Workshop Report: 4 Components of COPD Management Plan1) Assess and monitor disease
2) Reduce risk factors
3) Manage stable COPD
4) Manage exacerbations
04/08/23 131
Component 1: Assess and Monitor Disease KEY POINTS: Diagnosis of COPD is based on history of
exposure to risk factors and the presence of airflow limitation that is not fully reversible, w/ or without the presence of symptoms
Patients who have chronic cough and sputum production with a history of exposure to risk factors should be tested for airflow limitation, even if they do not have dyspnea
04/08/23 132
For the diagnosis and assessment of COPD, Spirometry is the gold standard, as it is the most reproducible, standardized, and objective way of measuring airflow limitation.
Health care workers involved in the diagnosis and management of COPD patients should have access to spirometry
Measurement of arterial blood gas tensions should be considered in all patients with FEV<40% predicted or clinical signs suggestive of respiratory failure or right heart failure
04/08/23 133
Component 2: Reduce Risk Factors KEY POINTS: Reduction of total personal exposure to
tobacco smoke, occupational dusts and chemicals and indoor and outdoor air pollutants are important goals to prevent the onset and progression of COPD
Smoking cessation is the single most effective- and cost effective – way in most people to reduce the risk of developing COPD and stop its regression
04/08/23 134
Brief tobacco dependence counseling is effective and every tobacco user should be offered at least this treatment at every visit to a health care provider
Several effective pharmacotherapies for tobacco dependence are available and at least one of these medications should be added to counseling if necessary and in the absence of contraindications
Progression of many occupationally induced respiratory disorders can be reduced or controlled through a variety of strategies aimed at reducing the burden of inhaled particles and gases
04/08/23 135
Component 3: Manage Stable COPD KEY POINTS: The overall approach to managing stable
COPD should be characterized by a stepwise increase in treatment, depending on the severity of the disease
Health education can play a role in improving skills, ability to cope with illness, and health status
04/08/23 136
Pharmacotherapy for COPD is used to decrease symptoms and/or complications
Bronchodilator medications are central to the symptomatic management of COPD, which are given on as-needed basis or on a regular basis to prevent or reduce symptoms
Regular treatment with long-acting bronchodilators is more effective and convenient than treatment with short-acting bronchodilators, but more expensive
Addition of regular treatment with inhaled glucocortisteroids to bronchodilator treatment is appropriate for symptomatic COPD patients - stage III and IV- and repeated exacerbations
04/08/23 137
Component 4: Manage Exacerbations KEY POINTS: Most common causes of an exacerbation are
infection of the tracheobronchial tree and air pollution, but 1/3 of the cause of severe exacerbations cannot be identified
Inhaled bronchodilators are effective treatment for exacerbation of COPD
04/08/23 138
Those with clinical symptoms of infections benefit from antibiotic treatment
Non-invasive intermittent positive pressure ventilation (NIPPV) in exacerbations improves the blood gases and pH, reduces hospital mortality decreases the need for invasive mechanical ventilation and intubation and decreased the length of hospital stay
04/08/23 139
Symptomatic therapy- A) Short acting bronchodilators B) Long acting inhaled anticholinergic agents
( tiotropium) C) Salmeterol – long acting B 2 agonist, formoterol Moderate- Severe COPD- FEV1 < 50% predicted
with two exacerbation per year. Inhaled corticosteroids Combined B 2 agonist and inhaled corticosteroids Theophyllines, mucolytics may still have a role
04/08/23 140
Pulmonary Rehabilitation – 7-8 weeks improve exercise capacity and quality of life.
Oxygen therapy –appropriate for patients who are hypoxemic at rest ( PaO2 less than or equal to 5.5 mm Hg or 56 to 59 mm Hg with evidence of end organ effects of the hypoxemia )
Treatment of exacerbation
04/08/23 141